Gleason Group’s Cue Biopharma CUE Stock Holding History

Gleason Group’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.17K	Hold	200	–	–	﹤0.01%	310
2026 Q2	$6.31K	Hold	200	–	–	﹤0.01%	287
2026 Q1	$1.38K	Hold	200	–	–	﹤0.01%	214
2025 Q4	$1.83K	Hold	200	–	–	﹤0.01%	208
2025 Q3	$4.31K	Hold	200	–	–	﹤0.01%	177
2025 Q2	$4.09K	Hold	200	–	–	﹤0.01%	182
2025 Q1	$5.47K	Hold	200	–	–	﹤0.01%	177
2024 Q4	$6.54K	Hold	200	–	–	﹤0.01%	179
2024 Q3	$4.54K	Hold	200	–	–	﹤0.01%	178
2024 Q2	$7.44K	Hold	200	–	–	﹤0.01%	204
2024 Q1	$11.3K	Hold	200	–	–	﹤0.01%	170
2023 Q4	$15.8K	Hold	200	–	–	﹤0.01%	160
2023 Q3	$13.8K	Hold	200	–	–	﹤0.01%	172
2023 Q2	$21.9K	Buy	+200	New	+$23.5K	0.01%	148

Other funds holding CUE

NFSG

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return

Gleason Group's CUE Position: Q3 2026 in Review

Gleason Group held its Cue Biopharma (CUE) position steady in Q3 2026 at 200 shares worth $5.17K. The position accounts for ﹤0.01% of the portfolio, ranked #310.

Gleason Group first reported a position in CUE in Q2 2023 and has held it in 14 quarters since. The position peaked at $21.9K in Q2 2023. 3 funds tracked by Wall St. Rank hold CUE as of Q3 2026.

Gleason Group held 200 shares of Cue Biopharma worth $5.17K as of Q3 2026.
Gleason Group left its Cue Biopharma share count unchanged in Q3 2026.
Cue Biopharma made up ﹤0.01% of Gleason Group's portfolio in Q3 2026, its #310 holding.
Gleason Group first reported a position in Cue Biopharma in Q2 2023 and has held it in 14 quarters since.
Gleason Group's Cue Biopharma position peaked at $21.9K in Q2 2023.
3 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2026.

Based on Gleason Group's 13F filing for Q3 2026, filed 15 Oct 2026.